Aim: According to World Health Organization, prostate cancer is one of the increasing malignancies in men worldwide. This paper aims to describe the epidemiological, clinical, diagnostic, therapeutic, and evolutionary aspects of patients with early metastatic prostate cancer in a urology center in the city of Douala in Cameroon. Materials and Methods: It is a retrospective and descriptive study of 110 patients with prostate cancer that was immediately metastatic at diagnosis over a period of six years (from January 2014 to December 2020). Results: The average age of patients at diagnosis was 67.5 years (range: 45 years to 88 years) and 53.63% of patients had body mass indexes greater than 25. Disorders of the lower urinary tract were the main presenting complaint in 55.45% of cases, followed by bone and joint pain in 46.36% of cases. Digital rectal examination was suggestive of prostate cancer in 96.36% of cases with an average total prostatic specific antigen (PSAT) level of 676.9 ng/ml (range: 21.8 to 8832 ng/ml). The diagnosis was made through prostate biopsy in 57 (51.81%) patients or after palliative endoscopic resection of the prostate indicated for lower urinary tract symptoms or even acute urinary retention in 53 (48.18%) patients. Adenocarcinoma of the prostate was the main histologic type, and in 47.27% of cases, the tumor was poorly differentiated with a Gleason’s score of greater than 7. The sites of metastasis were mainly the lymph node (87.27%), bone (56.36%), and both (44.54%). The treatment was palliative and dominated by bilateral pulpectomy in 60% of cases and luteinizing hormone-releasing hormone agonists (Triptorelin 11.25 mg every 3 months) in 44 (40%) of cases. Conclusion: Prostate cancer is a real public health problem in developed countries but also in Africa, especially in Cameroon. It is aggressive cancer that is often diagnosed when metastasis has already occurred. Its management is essentially palliative.
References
[1]
Okamoto, T., Hatakeyama, S., Narita, S., Arai, Y., Habuchi, T. and Ohyama, C. (2020) Validation and Development of the CHAARTED Criteria in Patients with Hormone-Naïve Metastatic Prostate Cancer: A Multi-Institutional Retrospective Study in Japan. International Journal of Urology, 27, 90-91. https://doi.org/10.1111/iju.14136
[2]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[3]
Rebbeck, T.R., Devesa, S.S., Chang, B.-L., Bunker, C.H., Cheng, I., Cooney, K., et al. (2013) Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent. Prostate Cancer, 2013, Article ID: 560857. https://doi.org/10.1155/2013/560857
[4]
Bensalah, K., Durand, X. and Murez, T. (2022) Actualisation 2020-2022 des recommandations françaises du Comité de cancérologie de l’AFU-Éditorial Update 2020-2022 of French ccAFU Guidelines-Editorial French ccAFU Guidelines-Update 2020-2022: Management of Kidney Cancer. Recommandations fr.
[5]
Jacquet, E., Lardy-Cléaud, A., Pistilli, B., Franck, S., Cottu, P., Delaloge, S., et al. (2018) Endocrine Therapy or Chemotherapy as First-Line Therapy in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients. European Journal of Cancer, 95, 93-101. https://doi.org/10.1016/j.ejca.2018.03.013
[6]
Moul, J.W. (2015) Hormone Naïve Prostate Cancer: Predicting and Maximizing Response Intervals. Asian Journal of Andrology, 17, 929-935. https://doi.org/10.4103/1008-682X.152821
[7]
Latorzeff, I., Bourgier, C., Pinel, B., Hennequin, C., Jimenez, G., Chapet, O., et al. (2019) Treatment of Primary Disease (Breast, Non-Small Cell Lung and Prostate Cancers) with Irradiation in Case of de Novo Metastatic Cancer. Cancer/Radiotherapie, 23, 486-495. https://doi.org/10.1016/j.canrad.2019.08.004
[8]
Laville, A., Coutte, A., Blanchard, P., Sun, R., Deutsch, E. and Latorzeff, I. (2020) Treatment of Primary Disease for Synchronous Metastatic Prostate Cancer. Cancer/Radiotherapie, 24, 547-553. https://doi.org/10.1016/j.canrad.2020.06.011
[9]
Niang, L., Ndoye, M., Ouattara, A., Jalloh, M., Labou, M., Thiam, I., et al. (2013) Cancer de la prostate: Quelle prise en charge au Sénégal? Management of Prostate Cancer in Senegal: What Is Being Done? Progrès en Urologie, 23, 36-41. https://doi.org/10.1016/j.purol.2012.09.002
[10]
Fofana, A., Kouame, B., Gowe, E.E., Kramo, N.A.F., Konan, K.P.G., Moro, A.C., et al. (2017) Cancer metastase de la prostate: Aspects socio-économiques, radiologiques et évolutifs en cote d’ivoire. African Journal of Urology, 23, 281-285. https://doi.org/10.1016/j.afju.2016.11.002
[11]
Chu, L.W., Ritchey, J., Devesa, S.S., Quraishi, S.M., Zhang, H. and Hsing, A.W. (2011) Prostate Cancer Incidence Rates in Africa. Prostate Cancer, 2011, Article ID: 947870. https://doi.org/10.1155/2011/947870
[12]
Steinberg, G.D., Carter, B.S., Beaty, T.H., Childs, B. and Walsh, P.C. (1990) Family History and the Risk of Prostate Cancer. The Prostate, 17, 337-347. https://doi.org/10.1002/pros.2990170409
[13]
Lesko, S.M., Rosenberg, L. and Shapiro, S. (1996) Family History and Prostate Cancer risk. American Journal of Epidemiology, 144, 1041-1047. https://doi.org/10.1093/oxfordjournals.aje.a008876
[14]
Kalish, L.A., McDougal, W.S. and McKinlay, J.B. (2000) Family History and the Risk of Prostate Cancer. Urology, 56, 803-806. https://doi.org/10.1016/S0090-4295(00)00780-9
[15]
Cuzick, J., Thorat, M.A., Andriole, G., Brawley, O.W., Brown, P.H., Culig, Z., et al. (2014) Prevention and Early Detection of Prostate Cancer. The Lancet Oncology, 15, e484-e492. https://doi.org/10.1016/S1470-2045(14)70211-6
[16]
Merriel, S.W.D., Funston, G. and Hamilton, W. (2018) Prostate Cancer in Primary Care. Advances in Therapy, 35, 1285-1294. https://doi.org/10.1007/s12325-018-0766-1
[17]
Engeland, A., Tretli, S. and Bjørge, T. (2003) Height, Body Mass Index, and Prostate Cancer: A Follow-Up of 950000 Norwegian Men. British Journal of Cancer, 89, 1237-1242. https://doi.org/10.1038/sj.bjc.6601206
[18]
Cao, Y. and Ma, J. (2011) Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: A Systematic Review and Meta-Analysis. Cancer Prevention Research (Phila Pa), 4, 486-501. https://doi.org/10.1158/1940-6207.CAPR-10-0229
[19]
Rodriguez, C., Freedland, S.J., Deka, A., Jacobs, E.J., McCullough, M.L., Patel, A.V., et al. (2007) Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology, Biomarkers & Prevention, 16, 63-69. https://doi.org/10.1158/1055-9965.EPI-06-0754
[20]
Giovannucci, E., Rimm, E.B., Liu, Y., Leitzmann, M., Wu, K., Stampfer, M.J., et al. (2003) Body Mass Index and Risk of Prostate Cancer in U.S. Health Professionals. Journal of the National Cancer Institute, 95, 1240-1244. https://doi.org/10.1093/jnci/djg009
[21]
Schröder, F.H., Van Der Maas, P., Beemsterboer, P., Kruger, A.B., Hoedemaeker, R., Rietbergen, J., et al. (1998) Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer. Journal of the National Cancer Institute, 90, 1817-1823. https://doi.org/10.1093/jnci/90.23.1817
[22]
Leslie, S.W., Soon-Sutton, T.L., Sajjad, H. and Siref, L.E. (2021) Prostate Cancer. In: StatPearls [Internet], StatPearls Publishing, Treasure Island, 1-10. http://www.ncbi.nlm.nih.gov/books/NBK470550
[23]
Freedland, S.J., Isaacs, W.B., Platz, E.A., Terris, M.K. and Aronson, W.J. (2021) Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression after Radical Prostatectomy: A Search Database Study. Journal of Clinical Oncology, 23, 7546-7554. https://doi.org/10.1200/JCO.2005.05.525
[24]
Young, M.J., et al. (1999) Complications of Advanced Prostate Cancer. Urology, 54, 8-14. https://doi.org/10.1016/S0090-4295(99)00448-3
[25]
Cornud, F. (2006) MRI and Staging Evaluation of Prostate Cancer. Journal de Radiologie, 87, 228-241. https://doi.org/10.1016/S0221-0363(06)73997-X
[26]
Cornud, F., Lecouvet, F. and Portalez, D. (2010) Impact of MRI in the Workup of Prostate Cancer. Progrès en Urologie—Formation Médicale Continue, 20, F13-F20. https://doi.org/10.1016/j.fpurol.2009.09.004
[27]
Lebret, T. (2011) Physiopathology and New Therapeutic Strategies in the Management of Bone Metastases of Prostate Cancer. Progrès en Urologie, 21, 301-307. https://doi.org/10.1016/j.purol.2010.12.001
[28]
Konan, P.G., Gowe, E.E., et al. (2015) Cancer métastatique de la prostate dans le service d’urologie du CHU de Cocody. Revue Africained’Urologie etd’Andrologie, 1, 172-176.
[29]
Ritch, C. and Cookson, M. (2018) Recent Trends in the Management of Advanced Prostate Cancer [Version 1; Peer Review: 3 Approved]. F1000Research, 7, 1-7. https://doi.org/10.12688/f1000research.15382.1
[30]
Ramamurthy, C., Handorf, E.A., Correa, A.F., et al. (2015) Cost-Effectiveness of Abiraterone versus Docetaxel in the Treatment of Metastatic Hormone Naïve Prostate Cancer. Urologic Oncology, 37, 688-695. https://doi.org/10.1016/j.urolonc.2019.05.017
[31]
Hamilou, Z., Saad, F. and Fizazi, K. (2018) Treatment of Hormone-Naive Metastatic Prostate Cancer. Current Opinion in Supportive and Palliative Care, 12, 334-338. https://doi.org/10.1097/SPC.0000000000000359
